HEALWELL AI (6H90) AI Stock Analysis

14 Followers

HEALWELL AI

(Frankfurt:6H90)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring Revenue BaseA 70% recurring-revenue mix provides greater visibility than episodic project work and can support more predictable planning, retention and cash generation. Continued subscription growth also strengthens the foundation for operating leverage as HEALWELL expands its healthcare software footprint.

Negative Factors

Persistent UnprofitabilityDespite revenue growth and narrower losses, HEALWELL has not yet demonstrated durable profitability or self-funded operations. Continued net losses and negative free cash flow can constrain investment capacity, increase reliance on financing, and make execution more sensitive to delays in reaching scale.

HEALWELL AI (6H90) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 180.19M
Dividend Yield: ―
Average Volume (3M): 6,618
Price to Earnings (P/E): -9.9
Beta (1Y): 0.82
Revenue Growth: 26.54%
EPS Growth: 81.57%
Country: Germany
Employees: 570
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

HEALWELL AI Business Overview & Revenue Model

Company Description

Healwell AI Inc., a Toronto-based healthcare technology firm established in 2012, specializes in leveraging artificial intelligence and data science to advance preventative medical care. The company develops an AI-powered platform designed to assist...

HEALWELL AI Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-16.47%|Next Earnings Date:May 16, 2022

Earnings Call SentimentPositive

The call was predominantly positive, with strong revenue and adjusted EBITDA growth, improved operating cash flow, expanding recurring revenue, major enterprise agreements, a stronger HIE pipeline and continued clinical validation of the AI platform. These positives were tempered by weak Q3 Life Sciences performance, a lower quarterly gross margin, declining reported Data Science and AI revenue, milestone-dependent revenue recognition, cash and debt considerations, and early-stage go-to-market capacity. Management remained confident in the transition toward recurring global healthcare-system and SaaS revenue.

Positive Updates

Quarterly Revenue and Adjusted EBITDA Growth

Q3 2026 revenue from continuing operations was $32.6 million, up 7% from $30.4 million in Q3 2025. Adjusted EBITDA was $1.6 million, up 144% from $0.7 million, supported by improved performance across operating segments and a 7% reduction in total operating expenses.

Negative Updates

Impact of Most Favored Nation Drug Pricing on Canada

Management said Most Favored Nation drug pricing has accelerated the shift away from episodic Canadian life sciences revenue. Canada is receiving new medications later or not at all; an industry survey cited at least 16 new medicines not launched in Canada in 2026 and more than 30 delayed. Management characterized the effect on HEALWELL as a delay rather than a loss of demand.

Company Guidance

Management said it targets a 10% growth rate on an annual basis and that a 10% growth rate is a reasonable expectation, while the adjusted EBITDA target of 10% will largely be hit depending on revenue recognition and key milestones; Converge Iowa is expected to have an annual impact north of $1 million, with an uptick in Q4, SMART deployment in early next year, and contracted revenue of over $1 million that won't be in this year's numbers. Management expects gross margins to gradually expand from realistic Q4 onwards, expects WELLTRUST revenue to appear in the coming quarters, with recognition in Q4 or Q1 depending on milestones, and said it expects procurement feedback and decisions on 19 named near-term opportunities through first quarter of 2027, with 2027 guidance by March. It expects another 1/3 of Orion cost synergies next year and the balance into 2028, while SG&A may show a couple more quarters of similar or slightly higher levels before bigger savings ahead.

HEALWELL AI Peers Comparison

Overall Rating

Financial Indicators

DE:6H90 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:6H90 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:6H90	Healwell Ai Inc.	0.35	-0.38	-52.05%
TSE:EKG	Cardiocomm Solutions	0.01	0.00	0.00%
TSE:RHT.H	Reliq Health Technologies	0.21	0.00	0.00%
TSE:JUMP	Leveljump Healthcare Corp.	0.06	-0.00	-8.33%
TSE:KOVO	Kovo HealthTech Corporation	0.01	-0.03	-75.00%
TSE:NURS	Hydreight Technologies Inc	3.13	-1.82	-36.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

HEALWELL AI AI Stock Analysis